← 產業報告目錄

Cell Therapy Technologies Market by Product (Media, Sera, Reagents, Vessels, Equipment), Process (Expansion, Isolation, Characterization, Collection, Preservation, Distribution, QC), Type (T-cells, Stem Cells), Application (Cancer) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-12-11頁數 432報告編號 BT6823

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global cell therapy technologies market is projected to reach USD 7.91 billion in 2030 from USD 4.41 billion in 2025, with a significant CAGR of 12.4% from 2025 to 2030. The market is experiencing strong growth, driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, along with strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, thereby driving market growth. “The T-cells segment is projected to record the highest CAGR during the forecast period.” The cell therapy technologies market is categorized into three primary categories based on cell type: T cells, stem cells, and other cell types. The T-cell segment is expected to grow at the fastest rate during the forecast period, driven by the strong clinical and commercial momentum of CAR-T and TCR therapies in cancer and their expansion into solid tumor indications. Furthermore, increasing regulatory approvals, favorable reimbursement decisions in significant markets, and growing physician familiarity with T-cell immunotherapies are encouraging broader adoption, which in turn boosts demand for specialized media, gene-editing tools, bioreactors, and analytics tailored to T-cell workflows within the cell therapy technology market. “The cancer application segment accounted for the largest share in 2024.” The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application segment dominated in 2024 due to the increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and government initiatives are highly supportive, with regulatory approvals facilitating the segment's growth. “The US dominated the North American cell therapy technologies market in 2024.” The US is the largest biopharmaceutical market globally and a key hub for cell and gene therapy innovation, making it a core demand center for cell therapy technologies, products, and services. Demand is expected to rise further, supported by a sophisticated research ecosystem, strong venture and public funding, and the presence of foremost CGT technology leaders, including Thermo Fisher Scientific, Danaher, and Merck. The country benefits from substantial NIH and BARDA support for advanced therapies, as well as large precision medicine and population‑scale CGT initiatives run through leading academic and cancer centers. The high uptake of automated cell processing platforms, digital manufacturing, and advanced analytics across clinical and commercial facilities reinforces the US market's leadership. In addition, a mature regulatory framework, robust healthcare infrastructure, and active public–private collaborations continue to foster rapid translation and commercialization of new cell therapy technologies in the US. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side (70%) and Demand Side (30%) • By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%) • By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market. Research Coverage: This research report categorizes the cell therapy technologies market by product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T-cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report’s scope encompasses detailed information regarding the key factors, including drivers, restraints, challenges, and opportunities, that influence market growth. A thorough analysis of key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are recent developments in the cell therapy technologies market. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (expanding base of approved CGTs and a growing clinical pipeline, growing capital investments in CGT manufacturing capacity, scale-up of allogeneic and iPSC-derived platforms) restraints (high therapy cost and uncertain reimbursement limiting commercial volumes), opportunities (platformized, modular manufacturing solutions for autologous therapies, integration with digital technologies such as AI & ML), and challenges (lack of skilled workforce in CGT manufacturing and automation) influencing the growth of the market. • Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market. • Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market. • Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), among others in the market.
目錄 Table of Contents
1 INTRODUCTION 40 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 40 1.3 STUDY SCOPE 40 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 41 1.3.2 INCLUSIONS & EXCLUSIONS 42 1.3.3 YEARS CONSIDERED 42 1.3.4 CURRENCY CONSIDERED 42 1.4 STAKEHOLDERS 43 1.5 SUMMARY OF CHANGES 43 2 EXECUTIVE SUMMARY 45 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 45 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46 2.3 DISRUPTIVE TRENDS SHAPING MARKET 47 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 48 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49 3 PREMIUM INSIGHTS 50 3.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 50 3.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY, 2024 51 3.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2025 VS. 2030 52 3.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52 4 MARKET OVERVIEW 53 4.1 INTRODUCTION 53 4.2 MARKET DYNAMICS 53 4.2.1 DRIVERS 54 4.2.1.1 Expanding base of approved CGTs and growing clinical pipeline 54 4.2.1.2 Large capital investments in CGT manufacturing capacity 54 4.2.1.3 Growing shift towards closed and automated manufacturing 55 4.2.2 RESTRAINTS 55 4.2.2.1 Manufacturing and logistical complexity 55 4.2.2.2 High therapy cost and uncertain reimbursement limit commercial volumes 56 4.2.3 OPPORTUNITIES 56 4.2.3.1 Platformized and modular manufacturing solutions for autologous therapies 56 4.2.3.2 Development of personalized and off-the-shelf cell therapies 57 4.2.3.3 Integration with digital technologies 57 4.2.4 CHALLENGES 58 4.2.4.1 Lack of skilled workforce in CGT manufacturing and automation 58 4.3 UNMET NEEDS & WHITE SPACES 58 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 59 4.5 STRATEGIC MOVES BY TIER 1/2/3 COMPANIES 59 5 INDUSTRY TRENDS 60 5.1 PORTER’S FIVE FORCES ANALYSIS 60 5.1.1 THREAT OF NEW ENTRANTS 61 5.1.2 THREAT OF SUBSTITUTES 61 5.1.3 BARGAINING POWER OF BUYERS 61 5.1.4 BARGAINING POWER OF SUPPLIERS 61 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 61 5.2 MACROECONOMIC OUTLOOK 62 5.2.1 INTRODUCTION 62 5.2.2 GDP TRENDS AND FORECAST 62 5.2.3 TRENDS IN CELL THERAPY TECHNOLOGIES MARKET 63 5.2.4 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 63 5.2.5 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 63 5.3 ECOSYSTEM ANALYSIS 64 5.3.1 ROLE IN ECOSYSTEM 64 5.4 PRICING ANALYSIS 65 5.4.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022–2024 66 5.4.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022–2024 67 5.5 VALUE CHAIN ANALYSIS 68 5.6 TRADE ANALYSIS 70 5.6.1 IMPORT SCENARIO FOR HS CODE 854330 70 5.6.2 IMPORT VOLUME FOR HS CODE 854330 71 5.6.3 EXPORT SCENARIO FOR HS CODE 854330, 2020–2024 71 5.6.4 EXPORT VOLUME FOR HS CODE 854330 72 5.7 KEY CONFERENCES AND EVENTS, 2026 73 5.8 INVESTMENT & FUNDING SCENARIO 73 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 75 5.10 IMPACT OF 2025 US TARIFF ON CELL THERAPY TECHNOLOGIES MARKET 76 5.10.1 KEY TARIFF RATES 76 5.10.2 PRICE IMPACT ANALYSIS 78 5.10.3 KEY IMPACT ON COUNTRIES/ REGION 78 5.10.3.1 US 78 5.10.3.2 Europe 79 5.10.3.3 Asia Pacific 79 5.10.4 END-USE INDUSTRY IMPACT 79 5.10.4.1 Biopharmaceutical and Biotechnology Companies 79 5.10.4.2 CROs and CMOs 80 5.10.4.3 Cell Banks 80 6 TECHNOLOGICAL ADVANCEMENTS, AI IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 81 6.1 TECHNOLOGY ANALYSIS 81 6.1.1 KEY EMERGING TECHNOLOGIES 81 6.1.1.1 Magnetic-activated cell sorting 81 6.1.1.2 Cryopreservation 81 6.1.1.3 Bioprocessing technologies 81 6.1.2 COMPLEMENTARY TECHNOLOGIES 82 6.1.2.1 Artificial intelligence and machine learning 82 6.1.2.2 Gene editing technologies 82 6.1.3 ADJACENT TECHNOLOGIES 82 6.1.3.1 Nanotechnology 82 6.1.3.2 Immunotherapy platforms 83 6.2 TECHNOLOGY/PRODUCT ROADMAP 83 6.3 PATENT ANALYSIS 83 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014–2024 84 6.4 FUTURE APPLICATIONS 86 6.5 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET 86 6.5.1 TOP USE CASES AND MARKET POTENTIAL 87 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET 88 6.5.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CELL THERAPY TECHNOLOGIES MARKET 88 7 SUSTAINABILITY AND REGULATORY LANDSCAPE 90 7.1 REGULATORY LANDSCAPE 90 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 7.1.2 INDUSTRY STANDARDS 92 7.1.2.1 North America 93 7.1.2.2 Europe 93 7.1.2.3 Asia Pacific 93 7.1.2.4 Rest of the World 94 7.1.3 SUSTAINABILITY INITIATIVES, IMPACT, AND REGULATORY POLICY INITIATIVES 94 7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 95 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 96 8.1 DECISION-MAKING PROCESS 96 8.2 KEY STAKEHOLDERS & BUYING CRITERIA 96 8.2.1 KEY STAKEHOLDERS 96 8.2.2 BUYING CRITERIA 97 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 99 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 100 9 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 101 9.1 INTRODUCTION 102 9.2 MEDIA, SERA, AND REAGENTS 102 9.2.1 KEY IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET 102 9.3 CELL THERAPY EQUIPMENT 106 9.3.1 CELL PROCESSING EQUIPMENT 109 9.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth 109 9.3.2 SINGLE-USE EQUIPMENT 112 9.3.2.1 Increasing funding for stem cell therapy to propel market growth 112 9.3.3 OTHER CELL THERAPY EQUIPMENT 115 9.4 SYSTEMS & SOFTWARE 117 9.4.1 GROWING NEED FOR CELL THERAPIES TO AID SYSTEMS AND SOFTWARE ADOPTION 117 9.5 CELL CULTURE VESSELS 121 9.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO AUGMENT MARKET DEMAND 121 9.6 CELL ENGINEERING PRODUCTS 123 9.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH 123 9.7 OTHER PRODUCTS 127 10 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 130 10.1 INTRODUCTION 131 10.2 CELL PROCESSING 131 10.2.1 CELL EXPANSION 134 10.2.1.1 Rising demand for personalized and regenerative therapies to drive market growth 134 10.2.2 CELL ISOLATION 137 10.2.2.1 Rising need for scalable and efficient isolation technologies to aid market growth 137 10.2.3 CELL CHARACTERIZATION 140 10.2.3.1 Increasing demand for high-quality, safe, and effective cell-based therapies to propel market growth 140   10.2.4 CELL COLLECTION 143 10.2.4.1 Advancements in cell collection technologies to propel market growth 143 10.3 CELL PRESERVATION 145 10.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO BOOST MARKET GROWTH 145 10.4 PROCESS MONITORING & QUALITY CONTROL 148 10.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO FUEL MARKET GROWTH 148 10.5 CELL HANDLING 151 10.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO ACCELERATE MARKET GROWTH 151 10.6 CELL DISTRIBUTION 154 10.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET 154 11 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 157 11.1 INTRODUCTION 158 11.2 T CELLS 158 11.2.1 GROWING RESEARCH ON CAR T-CELL THERAPY TO AID MARKET GROWTH 158 11.3 STEM CELLS 161 11.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET GROWTH 161 11.4 OTHER CELLS 164 12 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION 167 12.1 INTRODUCTION 168 12.2 CANCER 168 12.2.1 FOCUS ON CAR T-CELL INNOVATION TO DRIVE SEGMENT EXPANSION 168 12.3 CARDIOVASCULAR DISEASES 171 12.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET 171 12.4 ORTHOPEDIC DISORDERS 174 12.4.1 GROWING ADOPTION OF STEM CELL THERAPY FOR TISSUE REPAIR TO SUPPORT MARKET GROWTH 174 12.5 AUTOIMMUNE DISEASES 177 12.5.1 RISING INVESTMENTS IN STEM CELL RESEARCH TO FUEL MARKET GROWTH 177 12.6 OTHER APPLICATIONS 180 13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 184 13.1 INTRODUCTION 185 13.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 185 13.2.1 GROWING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH 185   13.3 CROS & CMOS 189 13.3.1 GROWING FOCUS ON OUTSOURCING CLINICAL-SCALE PRECLINICAL & CLINICAL TRIALS TO DRIVE GROWTH 189 13.4 RESEARCH INSTITUTES 192 13.4.1 RISING FOCUS ON RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 192 13.5 CELL BANKS 195 13.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SPUR MARKET GROWTH 195 14 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 199 14.1 INTRODUCTION 200 14.2 NORTH AMERICA 200 14.2.1 US 204 14.2.1.1 US to dominate North American cell therapy technologies market during forecast period 204 14.2.2 CANADA 207 14.2.2.1 Favorable funding scenario to drive adoption of cell therapy instruments 207 14.3 EUROPE 210 14.3.1 GERMANY 213 14.3.1.1 Well-established pharmaceutical and R&D industry to aid Germany gain significant European market share 213 14.3.2 UK 216 14.3.2.1 Favorable funding and investment scenario to fuel market growth 216 14.3.3 FRANCE 220 14.3.3.1 Availability of government and private funding to fuel market growth 220 14.3.4 ITALY 223 14.3.4.1 Increased focus on public and private investment to offer growth opportunities 223 14.3.5 SPAIN 226 14.3.5.1 Advancement in personalized medicines to stimulate market growth 226 14.3.6 REST OF EUROPE 229 14.4 ASIA PACIFIC 232 14.4.1 CHINA 235 14.4.1.1 Focus on innovation and R&D in genetic research to drive market 235 14.4.2 JAPAN 238 14.4.2.1 Strong availability of funding for advanced cell therapies to aid market growth 238 14.4.3 INDIA 241 14.4.3.1 Substantial government R&D investments and focus of academic institutions on scientific innovation to drive market 241 14.4.4 SOUTH KOREA 244 14.4.4.1 Rising number of alliances and investments in research to boost market growth 244   14.4.5 AUSTRALIA 247 14.4.5.1 Increasing government funding and initiatives to drive market growth 247 14.4.6 REST OF ASIA PACIFIC 250 14.5 LATIN AMERICA 253 14.5.1 BRAZIL 257 14.5.1.1 Growing development of advanced therapies and robust pharmaceutical & biotechnology sectors to aid market growth 257 14.5.2 MEXICO 260 14.5.2.1 Growing pharmaceutical industry and rising government support to aid market growth 260 14.5.3 REST OF LATIN AMERICA 263 14.6 MIDDLE EAST 266 14.6.1 GCC COUNTRIES 268 14.6.1.1 Kingdom of Saudi Arabia 271 14.6.1.1.1 Increasing government investments in healthcare to support market growth 271 14.6.1.2 UAE 275 14.6.1.2.1 Growing R&D expenditure and well-established class infrastructure to spur market growth 275 14.6.1.3 Rest of GCC Countries 278 14.6.2 REST OF MIDDLE EAST 281 14.7 AFRICA 283 14.7.1 INCREASING HEALTH AND RESEARCH SPENDING TO PROPEL MARKET DEMAND FOR ADVANCED CELL THERAPY TECHNOLOGIES 283 15 COMPETITIVE LANDSCAPE 287 15.1 INTRODUCTION 287 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 287 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET 287 15.3 REVENUE ANALYSIS, 2022–2024 288 15.4 MARKET SHARE ANALYSIS, 2024 289 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 291 15.5.1 STARS 291 15.5.2 EMERGING LEADERS 291 15.5.3 PERVASIVE PLAYERS 292 15.5.4 PARTICIPANTS 292 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 293 15.5.5.1 Company footprint 293 15.5.5.2 Region footprint 293 15.5.5.3 Product footprint 294 15.5.5.4 Cell type footprint 295 15.5.5.5 Application footprint 296   15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 297 15.6.1 PROGRESSIVE COMPANIES 297 15.6.2 RESPONSIVE COMPANIES 297 15.6.3 DYNAMIC COMPANIES 297 15.6.4 STARTING BLOCKS 297 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 298 15.6.5.1 Detailed list of key startups/SMEs 298 15.6.5.2 Competitive benchmarking of startups/SMEs 299 15.7 COMPANY VALUATION & FINANCIAL METRICS 300 15.7.1 FINANCIAL METRICS 300 15.7.2 COMPANY VALUATION 300 15.8 BRAND/PRODUCT COMPARISON 301 15.9 COMPETITIVE SCENARIO 301 15.9.1 PRODUCT LAUNCHES 301 15.9.2 DEALS 302 15.9.3 EXPANSIONS 303 16 COMPANY PROFILES 304 16.1 KEY PLAYERS 304 16.1.1 DANAHER CORPORATION 304 16.1.1.1 Business overview 304 16.1.1.2 Products offered 305 16.1.1.3 Recent developments 310 16.1.1.3.1 Product launches 310 16.1.1.3.2 Deals 310 16.1.1.3.3 Expansions 311 16.1.1.4 MnM view 312 16.1.1.4.1 Key strengths 312 16.1.1.4.2 Strategic choices 312 16.1.1.4.3 Weaknesses & competitive threats 312 16.1.2 MERCK KGAA 313 16.1.2.1 Business overview 313 16.1.2.2 Products offered 314 16.1.2.3 Recent developments 316 16.1.2.3.1 Deals 316 16.1.2.3.2 Expansions 317 16.1.2.4 MnM view 317 16.1.2.4.1 Key strengths 317 16.1.2.4.2 Strategic choices 317 16.1.2.4.3 Weaknesses & competitive threats 317   16.1.3 THERMO FISHER SCIENTIFIC INC. 318 16.1.3.1 Business overview 318 16.1.3.2 Products offered 319 16.1.3.3 Recent developments 330 16.1.3.3.1 Product launches 330 16.1.3.3.2 Deals 331 16.1.3.3.3 Expansions 331 16.1.3.4 MnM view 332 16.1.3.4.1 Key strengths 332 16.1.3.4.2 Strategic choices 332 16.1.3.4.3 Weaknesses & competitive threats 332 16.1.4 LONZA 333 16.1.4.1 Business overview 333 16.1.4.2 Products offered 334 16.1.4.3 Recent developments 338 16.1.4.3.1 Product launches 338 16.1.4.3.2 Deals 339 16.1.4.3.3 Expansions 339 16.1.4.4 MnM view 339 16.1.4.4.1 Key strengths 339 16.1.4.4.2 Strategic choices 340 16.1.4.4.3 Weaknesses & competitive threats 340 16.1.5 SARTORIUS AG 341 16.1.5.1 Business overview 341 16.1.5.2 Products offered 342 16.1.5.3 Recent developments 346 16.1.5.3.1 Deals 346 16.1.5.3.2 Expansions 346 16.1.5.4 MnM view 347 16.1.5.4.1 Key strengths 347 16.1.5.4.2 Strategic choices 347 16.1.5.4.3 Weaknesses & competitive threats 347 16.1.6 AGILENT TECHNOLOGIES, INC. 348 16.1.6.1 Business overview 348 16.1.6.2 Products offered 349 16.1.6.3 Recent developments 350 16.1.6.3.1 Product launches 350 16.1.6.3.2 Deals 351 16.1.6.4 MnM view 351 16.1.6.4.1 Key strengths 351 16.1.6.4.2 Strategic choices 351 16.1.6.4.3 Weaknesses & competitive threats 351 16.1.7 AVANTOR, INC. 352 16.1.7.1 Business overview 352 16.1.7.2 Products offered 353 16.1.7.3 Recent developments 359 16.1.7.3.1 Product launches 359 16.1.7.3.2 Deals 359 16.1.8 FRESENIUS SE & CO. KGAA 360 16.1.8.1 Business overview 360 16.1.8.2 Products offered 361 16.1.8.3 Recent developments 362 16.1.8.3.1 Deals 362 16.1.9 BECTON, DICKINSON AND COMPANY (BD) 363 16.1.9.1 Business overview 363 16.1.9.2 Products offered 364 16.1.9.3 Recent developments 366 16.1.9.3.1 Product launches 366 16.1.9.3.2 Deals 366 16.1.10 CORNING INCORPORATED 367 16.1.10.1 Business overview 367 16.1.10.2 Products offered 368 16.1.11 TERUMO CORPORATION 372 16.1.11.1 Business overview 372 16.1.11.2 Products offered 373 16.1.11.3 Recent developments 374 16.1.11.3.1 Product launches 374 16.1.11.3.2 Deals 374 16.1.11.3.3 Expansions 375 16.1.12 BIO-TECHNE 376 16.1.12.1 Business overview 376 16.1.12.2 Products offered 377 16.1.12.3 Recent developments 383 16.1.12.3.1 Product launches 383 16.1.12.3.2 Deals 383 16.1.12.3.3 Other developments 383 16.1.13 GENSCRIPT 384 16.1.13.1 Business overview 384 16.1.13.2 Products offered 385 16.1.13.3 Recent developments 387 16.1.13.3.1 Deals 387 16.1.13.3.2 Other developments 388   16.1.14 MAXCYTE 389 16.1.14.1 Business overview 389 16.1.14.2 Products offered 390 16.1.14.3 Recent developments 392 16.1.14.3.1 Deals 392 16.1.15 STEMCELL TECHNOLOGIES 394 16.1.15.1 Business overview 394 16.1.15.2 Products offered 394 16.1.15.3 Recent developments 400 16.1.15.3.1 Product launches 400 16.1.15.3.2 Deals 400 16.2 OTHER PLAYERS 401 16.2.1 ROOSTERBIO, INC. 401 16.2.2 MILTENYI BIOTEC 402 16.2.3 TRAKCEL 403 16.2.4 L7 INFORMATICS, INC. 404 16.2.5 REPLIGEN CORPORATION 405 16.2.6 MAK SYSTEM 406 16.2.7 ORIGEN BIOMEDICAL, INC. 407 16.2.8 IXCELLS BIOTECHNOLOGIES 408 16.2.9 KÖRBER AG 410 16.2.10 KRISHGEN BIOSYSTEMS 411 17 RESEARCH METHODOLOGY 412 17.1 RESEARCH DATA 412 17.1.1 SECONDARY DATA 412 17.1.1.1 Key objectives of secondary research 413 17.1.2 PRIMARY DATA 413 17.1.2.1 Breakdown of primaries 414 17.1.2.2 Objectives of primary research 414 17.2 MARKET ESTIMATION METHODOLOGY 415 17.2.1 MARKET ESTIMATION 415 17.2.2 INSIGHTS FROM PRIMARY EXPERTS 417 17.2.3 TOP-DOWN APPROACH 418 17.3 MARKET GROWTH RATE PROJECTIONS 419 17.4 DATA TRIANGULATION 421 17.5 STUDY ASSUMPTIONS 421 17.6 RESEARCH LIMITATIONS 422 17.7 RISK ANALYSIS 423   18 APPENDIX 424 18.1 DISCUSSION GUIDE 424 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 428 18.3 CUSTOMIZATION OPTIONS 430 18.4 RELATED REPORTS 430 18.5 AUTHOR DETAILS 431
圖表清單 List of Tables & Figures
TABLE 1 CELL THERAPY TECHNOLOGIES MARKET: INCLUSIONS & EXCLUSIONS 42 TABLE 2 IMPACT OF PORTER’S FIVE FORCES ON CELL THERAPY TECHNOLOGIES MARKET 61 TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM IN CELL THERAPY TECHNOLOGIES MARKET 64 TABLE 4 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 66 TABLE 5 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY REGION, 2022–2024 (USD) 67 TABLE 6 IMPORT VALUE FOR HS CODE 854330, 2020–2024 (USD THOUSAND) 70 TABLE 7 IMPORT VOLUME FOR HS CODE 854330, 2020–2024 (UNITS) 71 TABLE 8 EXPORT VALUE FOR HS CODE 854330, 2020–2024 (USD THOUSAND) 71 TABLE 9 EXPORT VOLUME FOR HS CODE 854330, 2020–2024 (UNITS) 72 TABLE 10 KEY CONFERENCES & EVENTS IN CELL THERAPY TECHNOLOGIES MARKET, JANUARY 2026–DECEMBER 2026 73 TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 76 TABLE 12 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO CELL THERAPY TECHNOLOGIES MARKET 78 TABLE 13 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS, 2025 84 TABLE 14 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET 88 TABLE 15 CLIENT’S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN CELL THERAPY TECHNOLOGIES MARKET 88 TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 20 VENDOR CERTIFICATIONS IN CELL THERAPY TECHNOLOGIES MARKET 95 TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS 97 TABLE 22 KEY BUYING CRITERIA FOR CELL THERAPY TECHNOLOGIES PRODUCTS, BY END USER 98 TABLE 23 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 102 TABLE 24 CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 25 NORTH AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 26 EUROPE: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 27 ASIA PACIFIC: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 28 LATIN AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 29 MIDDLE EAST: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 30 GCC COUNTRIES: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 31 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 106 TABLE 32 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 33 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 34 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 35 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 36 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 37 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 38 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 39 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 40 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 41 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 42 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 43 LATIN AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 44 MIDDLE EAST: CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 45 GCC COUNTRIES: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 46 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 47 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 48 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 49 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 50 LATIN AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 51 MIDDLE EAST: SINGLE-USE EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 52 GCC COUNTRIES: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 53 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 54 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 55 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 56 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 57 LATIN AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 58 MIDDLE EAST: OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 59 GCC COUNTRIES: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 60 MAJOR CELL THERAPY SYSTEMS & SOFTWARE, BY COMPANY 118 TABLE 61 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 62 NORTH AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 63 EUROPE: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 64 ASIA PACIFIC: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 65 LATIN AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 66 MIDDLE EAST: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 67 GCC COUNTRIES: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 68 CELL CULTURE VESSELS MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 69 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 70 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 71 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 72 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 73 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 74 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 75 CELL ENGINEERING PRODUCTS OFFERED BY KEY COMPANIES 124 TABLE 76 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 77 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 78 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 79 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 80 LATIN AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 81 MIDDLE EAST: CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 82 GCC COUNTRIES: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 83 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 84 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 85 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 86 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 87 LATIN AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 88 MIDDLE EAST: OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 89 GCC COUNTRIES: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 90 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 131 TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 132 TABLE 92 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 93 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 94 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 95 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 96 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 97 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 98 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 99 CELL EXPANSION MARKET, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 100 NORTH AMERICA: CELL EXPANSION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 101 EUROPE: CELL EXPANSION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 102 ASIA PACIFIC: CELL EXPANSION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 103 LATIN AMERICA: CELL EXPANSION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 104 MIDDLE EAST: CELL EXPANSION MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 105 GCC COUNTRIES: CELL EXPANSION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 106 CELL ISOLATION MARKET, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 107 NORTH AMERICA: CELL ISOLATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 108 EUROPE: CELL ISOLATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 109 ASIA PACIFIC: CELL ISOLATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 110 LATIN AMERICA: CELL ISOLATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 111 MIDDLE EAST: CELL ISOLATION MARKET, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 112 GCC COUNTRIES: CELL ISOLATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 113 CELL CHARACTERIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 114 NORTH AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 115 EUROPE: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 116 ASIA PACIFIC: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 117 LATIN AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 118 MIDDLE EAST: CELL CHARACTERIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 119 GCC COUNTRIES: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 120 CELL COLLECTION MARKET, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 121 NORTH AMERICA: CELL COLLECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 122 EUROPE: CELL COLLECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 123 ASIA PACIFIC: CELL COLLECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 124 LATIN AMERICA: CELL COLLECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 125 MIDDLE EAST: CELL COLLECTION MARKET, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 126 GCC COUNTRIES: CELL COLLECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 127 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 128 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 129 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 130 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 131 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 132 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 133 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 134 PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 135 NORTH AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 136 EUROPE: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 137 ASIA PACIFIC: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 138 LATIN AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 139 MIDDLE EAST: PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 140 GCC COUNTRIES: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 141 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 142 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 143 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 144 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 145 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 146 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 147 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 148 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 149 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 150 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 151 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 152 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 153 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 154 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 155 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 158 TABLE 156 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 157 NORTH AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 158 EUROPE: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 159 ASIA PACIFIC: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 160 LATIN AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 161 MIDDLE EAST: T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 162 GCC COUNTRIES: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 163 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 164 NORTH AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 165 EUROPE: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 166 ASIA PACIFIC: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 167 LATIN AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 168 MIDDLE EAST: STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 169 GCC COUNTRIES: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 170 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 171 NORTH AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 172 EUROPE: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 173 ASIA PACIFIC: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 174 LATIN AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 175 MIDDLE EAST: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 176 GCC COUNTRIES: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 177 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 168 TABLE 178 CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 179 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 180 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 181 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 183 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 184 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 185 CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 186 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 187 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 188 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 189 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 190 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 191 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 192 CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 193 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 194 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 195 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 196 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 197 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 177 TABLE 198 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 199 CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 200 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 201 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 202 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 203 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 204 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 180 TABLE 205 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 206 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 207 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 208 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 209 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 210 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 211 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 212 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 213 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 185 TABLE 214 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 215 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 216 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 217 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 218 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 219 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 220 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 221 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 222 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 223 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 224 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 225 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 226 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 227 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 228 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 229 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 230 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 231 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 232 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 233 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 234 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 235 CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2023–2030 (USD MILLION) 196 TABLE 236 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 237 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 238 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 239 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 240 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 241 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 242 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 200 TABLE 243 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 244 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 202 TABLE 245 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 246 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 202 TABLE 247 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 203 TABLE 248 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 203 TABLE 249 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 203 TABLE 250 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) TABLE 251 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 205 TABLE 252 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 253 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 205 TABLE 254 US: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 206 TABLE 255 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 206 TABLE 256 US: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 257 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 207 TABLE 258 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 208 TABLE 259 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 260 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 208 TABLE 261 CANADA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 262 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 209 TABLE 263 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 264 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 265 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 211 TABLE 266 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 267 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 211 TABLE 268 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 212 TABLE 269 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 212 TABLE 270 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 271 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 272 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 214 TABLE 273 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 274 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 215 TABLE 275 GERMANY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 215 TABLE 276 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 215 TABLE 277 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216 TABLE 278 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 216 TABLE 279 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 217 TABLE 280 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 281 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 218 TABLE 282 UK: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 283 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 219 TABLE 284 UK: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 219 TABLE 285 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 286 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 220 TABLE 287 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 288 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 221 TABLE 289 FRANCE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 290 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 222 TABLE 291 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 222 TABLE 292 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 222 TABLE 293 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 223 TABLE 294 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 295 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 224 TABLE 296 ITALY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 297 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 225 TABLE 298 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 225 TABLE 299 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 225 TABLE 300 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 226 TABLE 301 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 302 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 227 TABLE 303 SPAIN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 304 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 228 TABLE 305 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 228 TABLE 306 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 228 TABLE 307 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 229 TABLE 308 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 309 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 230 TABLE 310 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 311 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 231 TABLE 312 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 313 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 231 TABLE 314 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 233 TABLE 315 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 316 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 233 TABLE 317 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 318 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 234 TABLE 319 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 320 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 321 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 236 TABLE 322 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 323 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 236 TABLE 324 CHINA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 325 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 237 TABLE 326 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 327 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 328 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 239 TABLE 329 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 330 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 240 TABLE 331 JAPAN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 332 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 240 TABLE 333 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 241 TABLE 334 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 335 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 242 TABLE 336 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 337 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 243 TABLE 338 INDIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 339 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 243 TABLE 340 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 244 TABLE 341 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 342 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 245 TABLE 343 SOUTH KOREA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 344 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 246 TABLE 345 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 346 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 246 TABLE 347 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 247 TABLE 348 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 349 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 248 TABLE 350 AUSTRALIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 351 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 249 TABLE 352 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 353 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 249 TABLE 354 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 250 TABLE 355 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 250 TABLE 356 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 251 TABLE 357 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 358 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 252 TABLE 359 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 360 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 252 TABLE 361 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 362 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 253 TABLE 363 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 254 TABLE 364 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 254 TABLE 365 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 366 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 255 TABLE 367 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 368 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 256 TABLE 369 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 370 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 256 TABLE 371 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 257 TABLE 372 BRAZIL: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 373 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 258 TABLE 374 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 375 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 259 TABLE 376 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 259 TABLE 377 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 259 TABLE 378 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 260 TABLE 379 MEXICO: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 380 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 261 TABLE 381 MEXICO: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 382 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 262 TABLE 383 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262 TABLE 384 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 262 TABLE 385 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 263 TABLE 386 REST OF LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 387 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 264 TABLE 388 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 389 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 265 TABLE 390 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 265 TABLE 391 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 265 TABLE 392 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 266 TABLE 393 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 394 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 267 TABLE 395 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 396 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 267 TABLE 397 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 398 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 268 TABLE 399 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 269 TABLE 400 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 269 TABLE 401 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 402 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 270 TABLE 403 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 404 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 270 TABLE 405 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 271 TABLE 406 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 271 TABLE 407 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 272 TABLE 408 KINGDOM OF SAUDI ARABIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 409 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 273 TABLE 410 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 411 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 274 TABLE 412 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 413 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 274 TABLE 414 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 275 TABLE 415 UAE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 416 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 276 TABLE 417 UAE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 418 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 277 TABLE 419 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 277 TABLE 420 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 277 TABLE 421 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 278 TABLE 422 REST OF GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 423 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 279 TABLE 424 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 425 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 280 TABLE 426 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 280 TABLE 427 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 428 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 281 TABLE 429 REST OF MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 430 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 282 TABLE 431 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 432 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 282 TABLE 433 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 283 TABLE 434 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 435 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 284 TABLE 436 AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 437 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 285 TABLE 438 AFRICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 439 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 285 TABLE 440 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 286 TABLE 441 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 286 TABLE 442 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2022–2024 287 TABLE 443 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 290 TABLE 444 CELL THERAPY TECHNOLOGIES MARKET: REGION FOOTPRINT 293 TABLE 445 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 294 TABLE 446 CELL THERAPY TECHNOLOGIES MARKET: CELL TYPE FOOTPRINT 295 TABLE 447 CELL THERAPY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT 296 TABLE 448 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 298 TABLE 449 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY PRODUCT AND REGION 299 TABLE 450 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 301 TABLE 451 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2022–DECEMBER 2025 302 TABLE 452 CELL THERAPY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2025 303 TABLE 453 DANAHER CORPORATION: COMPANY OVERVIEW 304 TABLE 454 DANAHER CORPORATION: PRODUCTS OFFERED 305 TABLE 455 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 310 TABLE 456 DANAHER CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 310 TABLE 457 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–DECEMBER 2025 311 TABLE 458 MERCK KGAA: COMPANY OVERVIEW 313 TABLE 459 MERCK KGAA: PRODUCTS OFFERED 314 TABLE 460 MERCK KGAA: DEALS, JANUARY 2022–DECEMBER 2025 316 TABLE 461 MERCK KGAA: EXPANSIONS, JANUARY 2022–DECEMBER 2025 317 TABLE 462 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 318 TABLE 463 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 319 TABLE 464 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 330 TABLE 465 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–DECEMBER 2025 331 TABLE 466 THERMO FISHER SCIENTIFIC INC: EXPANSIONS, JANUARY 2021–OCTOBER 2024 331 TABLE 467 LONZA: COMPANY OVERVIEW 333 TABLE 468 LONZA: PRODUCTS OFFERED 334 TABLE 469 LONZA: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 338 TABLE 470 LONZA: DEALS, JANUARY 2022–DECEMBER 2025 339 TABLE 471 LONZA: EXPANSIONS, JANUARY 2022–DECEMBER 2025 339 TABLE 472 SARTORIUS AG: COMPANY OVERVIEW 341 TABLE 473 SARTORIUS AG: PRODUCTS OFFERED 342 TABLE 474 SARTORIUS AG: DEALS, JANUARY 2022–DECEMBER 2025 346 TABLE 475 SARTORIUS AG: EXPANSIONS, JANUARY 2022–DECEMBER 2025 346 TABLE 476 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 348 TABLE 477 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 349 TABLE 478 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 350 TABLE 479 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022– DECEMBER 2025 351 TABLE 480 AVANTOR, INC.: COMPANY OVERVIEW 352 TABLE 481 AVANTOR, INC.: PRODUCTS OFFERED 353 TABLE 482 AVANTOR, INC.: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 359 TABLE 483 AVANTOR, INC.: DEALS, JANUARY 2022–DECEMBER 2025 359 TABLE 484 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 360 TABLE 485 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 361 TABLE 486 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2022–DECEMBER 2025 362 TABLE 487 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 363 TABLE 488 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 364 TABLE 489 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 366 TABLE 490 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022–DECEMBER 2025 366 TABLE 491 CORNING INCORPORATED: COMPANY OVERVIEW 367 TABLE 492 CORNING INCORPORATED: PRODUCTS OFFERED 368 TABLE 493 TERUMO CORPORATION: COMPANY OVERVIEW 372 TABLE 494 TERUMO CORPORATION: PRODUCTS OFFERED 373 TABLE 495 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 374 TABLE 496 TERUMO CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 374 TABLE 497 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–DECEMBER 2025 375 TABLE 498 BIO-TECHNE: COMPANY OVERVIEW 376 TABLE 499 BIO-TECHNE: PRODUCTS OFFERED 377 TABLE 500 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 383 TABLE 501 BIO-TECHNE: DEALS, JANUARY 2022–DECEMBER 2025 383 TABLE 502 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 383 TABLE 503 GENSCRIPT: COMPANY OVERVIEW 384 TABLE 504 GENSCRIPT: PRODUCTS OFFERED 385 TABLE 505 GENSCRIPT: DEALS, JANUARY 2022–DECEMBER 2025 387 TABLE 506 GENSCRIPT: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 388 TABLE 507 MAXCYTE: COMPANY OVERVIEW 389 TABLE 508 MAXCYTE: PRODUCTS OFFERED 390 TABLE 509 MAXCYTE: DEALS, JANUARY 2022–DECEMBER 2024 392 TABLE 510 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 394 TABLE 511 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED 394 TABLE 512 STEMCELL TECHNOLOGIES: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 400 TABLE 513 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2022–DECEMBER 2025 400 TABLE 514 ROOSTERBIO, INC.: COMPANY OVERVIEW 401 TABLE 515 MILTENYI BIOTEC: COMPANY OVERVIEW 402 TABLE 516 TRAKCEL: COMPANY OVERVIEW 403 TABLE 517 L7 INFORMATICS, INC.: COMPANY OVERVIEW 404 TABLE 518 REPLIGEN CORPORATION: COMPANY OVERVIEW 405 TABLE 519 MAK SYSTEM: COMPANY OVERVIEW 406 TABLE 520 ORIGEN BIOMEDICAL, INC.: COMPANY OVERVIEW 407 TABLE 521 IXCELLS BIOTECHNOLOGIES: COMPANY OVERVIEW 408 TABLE 522 KÖRBER AG: COMPANY OVERVIEW 410 TABLE 523 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW 411 TABLE 524 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 420 TABLE 525 CELL THERAPY TECHNOLOGIES MARKET: RISK ANALYSIS 423 FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION & REGIONAL SCOPE 41 FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: YEARS CONSIDERED 42 FIGURE 3 MARKET SCENARIO OF CELL THERAPY TECHNOLOGIES MARKET 45 FIGURE 4 GLOBAL CELL THERAPY TECHNOLOGIES MARKET, 2023–2030 (USD MILLION) 46 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2020–2025 46 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF CELL THERAPY TECHNOLOGIES MARKET 47 FIGURE 7 HIGH-GROWTH SEGMENTS IN CELL THERAPY TECHNOLOGIES MARKET, 2025–2030 48 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CELL THERAPY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 49 FIGURE 9 INCREASED FUNDING & INVESTMENT IN CELL THERAPY AND GROWING PRODUCT PIPELINE TO DRIVE MARKET 50 FIGURE 10 US AND T-CELLS DOMINATED LARGEST NORTH AMERCIAN MARKET SHARE IN 2024 51 FIGURE 11 MEDIA, SERA, AND REAGENTS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD 52 FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52 FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53 FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 60 FIGURE 15 GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECAST UNTIL 2030 62 FIGURE 16 CELL THERAPY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS 64 FIGURE 17 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2024 (USD) 68 FIGURE 18 VALUE CHAIN ANALYSIS IN CELL THERAPY TECHNOLOGIES MARKET 69 FIGURE 19 GOVERNMENT FUNDING FOR R&D, 2019–2024 75 FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN CELL THERAPY TECHNOLOGIES MARKET 75 FIGURE 21 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014–2024 84 FIGURE 22 IMPACT OF AI IN CELL THERAPY TECHNOLOGIES MARKET 87 FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 97 FIGURE 24 KEY BUYING CRITERIA FOR END USERS 98 FIGURE 25 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 201 FIGURE 26 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 232 FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2022–2024 (USD MILLION) 289 FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET (2024) 290 FIGURE 29 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 292 FIGURE 30 CELL THERAPY TECHNOLOGIES MARKET: COMPANY FOOTPRINT 293 FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 298 FIGURE 32 EV/EBITDA OF KEY VENDORS 300 FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 300 FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 301 FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT 305 FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT 314 FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 319 FIGURE 38 LONZA: COMPANY SNAPSHOT 334 FIGURE 39 SARTORIUS AG: COMPANY SNAPSHOT 342 FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 349 FIGURE 41 AVANTOR, INC.: COMPANY SNAPSHOT 353 FIGURE 42 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT 361 FIGURE 43 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 364 FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT 368 FIGURE 45 TERUMO CORPORATION: COMPANY SNAPSHOT 373 FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT 377 FIGURE 47 GENSCRIPT: COMPANY SNAPSHOT 385 FIGURE 48 MAXCYTE: COMPANY SNAPSHOT 390 FIGURE 49 CELL THERAPY TECHNOLOGIES MARKET: RESEARCH DESIGN 412 FIGURE 50 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 414 FIGURE 51 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 415 FIGURE 52 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024 416 FIGURE 53 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE SHARE ANALYSIS (2024) 416 FIGURE 54 CELL THERAPY TECHNOLOGIES MARKET SIZE VALIDATION FROM PRIMARY SOURCES 417 FIGURE 55 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 418 FIGURE 56 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS 419 FIGURE 57 CELL THERAPY TECHNOLOGIES MARKET: DATA TRIANGULATION METHODOLOGY 421

同分類最新報告(醫療與生命科學)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們